New GLP-1 pill delivers up to 12% weight loss in 36 weeks
A new oral GLP-1 treatment, aleniglipron, enabled adults with obesity to lose up to 12 percent of their body weight over 36 weeks in a phase II clinical trial. This small-molecule drug, unlike existing injectable GLP-1 medications, can be taken orally, potentially improving accessibility and manufacturing efficiency. Conducted across 38 U.S. medical centers, the trial involved 230 participants who received varying doses of aleniglipron daily.